{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:51:50Z","timestamp":1792428710792,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1002\/jps.24471","type":"journal-article","created":{"date-parts":[[2015,5,18]],"date-time":"2015-05-18T22:56:55Z","timestamp":1431989815000},"page":"2233-2240","source":"Crossref","is-referenced-by-count":5,"title":["Investigating Detrusor Muscle Concentrations of Oxybutynin After Intravesical Delivery in an Ex Vivo Porcine Model"],"prefix":"10.1016","volume":"104","author":[{"given":"Nicholas A.","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris J.","family":"Allender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna L.","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gumbleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Harrah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Raja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hrishi B.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5 Suppl 2","key":"10.1002\/jps.24471_bb0005","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.5489\/cuaj.11183","article-title":"Symptom-based diagnosis of overactive bladder: An overview","volume":"5","author":"Wein","year":"2011","journal-title":"Can Urol Assoc J"},{"issue":"6 Suppl","key":"10.1002\/jps.24471_bb0010","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.juro.2012.09.079","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline","volume":"188","author":"Gormley","year":"2012","journal-title":"J Urol"},{"issue":"5","key":"10.1002\/jps.24471_bb0015","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1742-1241.2010.02626.x","article-title":"Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: A systematic review of the literature","volume":"65","author":"Sexton","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1002\/jps.24471_bb0020","series-title":"Section\u00a07.4.2 drugs for urinary frequency, enuresis and incontinence. British National Formulary","first-page":"1128","year":"2013"},{"issue":"7","key":"10.1002\/jps.24471_bb0025","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4172\/2161-0665.1000138","article-title":"Intravesical oxybutynin for neurogenic bladder in children","volume":"2","author":"Inoue","year":"2012","journal-title":"Pediat Therapeut"},{"issue":"6","key":"10.1002\/jps.24471_bb0030","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/S0022-5347(17)41304-8","article-title":"Topical oxybutynin chloride for relaxation of dysfunctional bladders","volume":"141","author":"Brendler","year":"1989","journal-title":"J Urol"},{"issue":"6","key":"10.1002\/jps.24471_bb0035","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0090-4295(93)90098-U","article-title":"Intravesical oxybutynin chloride: Experience with 42 patients","volume":"41","author":"Weese","year":"1993","journal-title":"Urology"},{"issue":"3 Pt 1","key":"10.1002\/jps.24471_bb0040","first-page":"892","article-title":"Intravesical oxybutynin for neurogenic bladder dysfunction: Less systemic side effects due to reduced first pass metabolism","volume":"160","author":"Buyse","year":"1998","journal-title":"J Urol"},{"issue":"5A Suppl","key":"10.1002\/jps.24471_bb0045","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0090-4295(99)00498-7","article-title":"Intravesical treatment of overactive bladder","volume":"55","author":"Fowler","year":"2000","journal-title":"Urology"},{"issue":"3","key":"10.1002\/jps.24471_bb0050","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.eururo.2007.02.059","article-title":"Editorial Comment on: Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve","volume":"52","author":"Reitz","year":"2007","journal-title":"Eur Urol"},{"issue":"6 Suppl","key":"10.1002\/jps.24471_bb0055","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/nau.20487","article-title":"Lower urinary tract symptoms (LUTS) and bladder afferent activity","volume":"26","author":"Yoshimura","year":"2007","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"10.1002\/jps.24471_bb0060","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(03)00622-7","article-title":"Antimuscarinics for treatment of overactive bladder","volume":"3","author":"Andersson","year":"2004","journal-title":"Lancet Neurol"},{"key":"10.1002\/jps.24471_bb0065","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4137\/CMT.S4606","article-title":"Muscarinic receptor antagonists, the overactive bladder and efficacy against urinary urgency","volume":"2","author":"Mansfield","year":"2010","journal-title":"Clin Med Insights Ther"},{"key":"10.1002\/jps.24471_bb0070","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0079-6123(05)52005-3","article-title":"Mechanisms underlying the recovery of lower urinary tract function following spinal cord injury","volume":"152","author":"De Groat","year":"2006","journal-title":"Prog Brain Res"},{"issue":"1","key":"10.1002\/jps.24471_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0302-2838(02)00540-7","article-title":"Antimuscarinics and the overactive detrusor\u2014Which is the main mechanism of action?","volume":"43","author":"Andersson","year":"2003","journal-title":"Eur Urol"},{"issue":"3","key":"10.1002\/jps.24471_bb0080","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","article-title":"The effects of antimuscarinic treatments in overactive bladder: An update of a systematic review and meta-analysis","volume":"54","author":"Chapple","year":"2008","journal-title":"Eur Urol"},{"issue":"3","key":"10.1002\/jps.24471_bb0085","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1464-410X.2006.06258.x","article-title":"Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: Motor or sensory actions?","volume":"98","author":"Finney","year":"2006","journal-title":"BJU Int"},{"key":"10.1002\/jps.24471_bb0090","series-title":"Nervous control of the urogenital system","first-page":"227","article-title":"Neurophysiology of micturition and its modification in animal models of human disease","author":"De Groat","year":"1993"},{"key":"10.1002\/jps.24471_bb0095","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.brainres.2010.09.018","article-title":"Effects of stimulation of muscarinic receptors on bladder afferent nerves in the in vitro bladder-pelvic afferent nerve preparation of the rat","volume":"1361","author":"Yu","year":"2010","journal-title":"Brain Res"},{"issue":"3","key":"10.1002\/jps.24471_bb0100","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.eururo.2010.11.040","article-title":"Antimuscarinic mechanisms and the overactive detrusor: An update","volume":"59","author":"Andersson","year":"2011","journal-title":"Eur Urol"},{"issue":"4","key":"10.1002\/jps.24471_bb0105","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.urology.2009.12.013","article-title":"Differential roles of M2 and M3 muscarinic receptor subtypes in modulation of bladder afferent activity in rats","volume":"75","author":"Matsumoto","year":"2010","journal-title":"Urology"},{"issue":"5","key":"10.1002\/jps.24471_bb0110","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.juro.2013.05.011","article-title":"Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: Results of an open label, randomized, prospective clinical study","volume":"190","author":"Krause","year":"2013","journal-title":"J Urol"},{"issue":"1","key":"10.1002\/jps.24471_bb0115","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/003655902317259319","article-title":"Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity","volume":"36","author":"Lehtoranta","year":"2002","journal-title":"Scand J Urol Nephrol"},{"issue":"1","key":"10.1002\/jps.24471_bb0120","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/00005392-199707000-00076","article-title":"Electromotive administration of oxybutynin into the human bladder wall","volume":"158","author":"Di Stasi","year":"1997","journal-title":"J Urol"},{"issue":"6","key":"10.1002\/jps.24471_bb0125","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00240-013-0608-1","article-title":"Stent encrustation in feline and human artificial urine: Does the low molecular weight composition account for the difference?","volume":"41","author":"Shafat","year":"2013","journal-title":"Urolithiasis"},{"key":"10.1002\/jps.24471_bb0130","unstructured":"Sigma-Aldrich. Product information sheet: Oxybutynin chloride 98% (TLC) powder. Accessed May 4, 2014, at: https:\/\/www.sigmaaldrich.com\/content\/dam\/sigmaaldrich\/docs\/Sigma\/Product_Information Sheet\/d8418pis.pdf."},{"key":"10.1002\/jps.24471_bb0135","series-title":"Promising pharmaceuticals","first-page":"83","article-title":"Apparent solubility and dissolution profile at non-sink conditions as quality improvement tools","author":"Petralito","year":"2012"},{"issue":"1","key":"10.1002\/jps.24471_bb0140","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0014-2999(02)02478-0","article-title":"Different responses to drugs against overactive bladder in detrusor muscle of pig, guinea pig and mouse","volume":"454","author":"W\u00fcst","year":"2002","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.1002\/jps.24471_bb0145","first-page":"1104","article-title":"Tool development for prediction of pIC50 values from IC50 values\u2014A pIC50 value calculator","volume":"5","author":"Selvaraj","year":"2011","journal-title":"Trends Biotechnol Pharm"},{"issue":"4","key":"10.1002\/jps.24471_bb0150","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00192-012-1915-8","article-title":"Oxybutynin: Past, present, and future","volume":"24","author":"Jirschele","year":"2013","journal-title":"Int Urogynecol J"},{"issue":"2","key":"10.1002\/jps.24471_bb0155","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/nau.20208","article-title":"Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: New insights into the working mechanism of antimuscarinics","volume":"25","author":"De Laet","year":"2006","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"10.1002\/jps.24471_bb0160","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.urology.2004.11.021","article-title":"Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways","volume":"65","author":"Kim","year":"2005","journal-title":"Urology"},{"issue":"3","key":"10.1002\/jps.24471_bb0165","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.eururo.2007.02.057","article-title":"Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve","volume":"52","author":"Iijima","year":"2007","journal-title":"Eur Urol"},{"issue":"1","key":"10.1002\/jps.24471_bb0170","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.urology.2008.04.038","article-title":"Effect of long-term oxybutynin administration on c-Fos expression in spinal neurons: Inhibition of antimuscarinics on bladder afferents in conscious rats","volume":"73","author":"Haga","year":"2009","journal-title":"Urology"},{"issue":"8","key":"10.1002\/jps.24471_bb0175","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1523\/JNEUROSCI.4694-07.2008","article-title":"Activation of muscarinic receptors in rat bladder sensory pathways alters reflex bladder activity","volume":"28","author":"Kullmann","year":"2008","journal-title":"J Neurosci"},{"issue":"5","key":"10.1002\/jps.24471_bb0180","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1097\/01.ju.0000176793.50410.9e","article-title":"Effects of tolterodine on an overactive bladder depend on suppression of C-fiber bladder afferent activity in rats","volume":"174","author":"Yokoyama","year":"2005","journal-title":"J Urol"},{"issue":"4 Pt 1","key":"10.1002\/jps.24471_bb0185","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.juro.2006.06.088","article-title":"Qualitative and quantitative expression profile of muscarinic receptors in human urothelium and detrusor","volume":"176","author":"Tyagi","year":"2006","journal-title":"J Urol"},{"issue":"1","key":"10.1002\/jps.24471_bb0190","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0022-5347(06)00563-5","article-title":"Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations","volume":"176","author":"Mukerji","year":"2006","journal-title":"J Urol"},{"issue":"2","key":"10.1002\/jps.24471_bb0195","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00280-010-1499-2","article-title":"The uptake of paclitaxel and docetaxel into ex vivo porcine bladder tissue from polymeric micelle formulations","volume":"68","author":"Tsallas","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1002\/jps.24471_bb0200","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.biomaterials.2011.09.081","article-title":"Tissue uptake of docetaxel loaded hydrophobically derivatized hyperbranched polyglycerols and their effects on the morphology of the bladder urothelium","volume":"33","author":"Mugabe","year":"2012","journal-title":"Biomaterials"},{"issue":"3","key":"10.1002\/jps.24471_bb0205","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1021\/mp400274z","article-title":"An ex vivo investigation into the transurothelial permeability and bladder wall distribution of the nonsteroidal anti-inflammatory ketorolac","volume":"11","author":"Williams","year":"2014","journal-title":"Mol Pharm"},{"issue":"5","key":"10.1002\/jps.24471_bb0210","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00467-007-0691-z","article-title":"The neurogenic bladder: Medical treatment","volume":"23","author":"Verpoorten","year":"2008","journal-title":"Pediatr Nephrol Berl Ger"},{"issue":"9","key":"10.1002\/jps.24471_bb0215","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1046\/j.1464-410x.2001.02227.x","article-title":"Intravesical oxybutynin for treating incontinence resulting from an overactive detrusor","volume":"87","author":"Lose","year":"2001","journal-title":"BJU Int"},{"issue":"1","key":"10.1002\/jps.24471_bb0220","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/nau.1930140111","article-title":"Intravesical oxybutynin in patients with posterior rhizotomies and sacral anterior root stimulators","volume":"14","author":"Singh","year":"1995","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"10.1002\/jps.24471_bb0225","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0022-5347(01)67394-4","article-title":"Histologic studies of intravesical oxybutynin in the rabbit","volume":"153","author":"Landau","year":"1995","journal-title":"J Urol"},{"issue":"1-2","key":"10.1002\/jps.24471_bb0230","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijpharm.2014.01.021","article-title":"Bladder tissue permeability and transport modelling of intravesical alum, lidocaine hydrochloride, methylprednisolone hemisuccinate and mitomycin C","volume":"464","author":"Moch","year":"2014","journal-title":"Int J Pharm"},{"issue":"4","key":"10.1002\/jps.24471_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2013.02.2490","article-title":"Abstract 2071: An ex vivo investigation into the viability of delivering \u201c-blockers locally for ureteral stent-related discomfort","volume":"189","author":"Williams","year":"2013","journal-title":"J Urol"},{"issue":"3","key":"10.1002\/jps.24471_bb0240","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1023\/A:1017595401988","article-title":"Intravesical oxybutynin affects bladder permeability","volume":"32","author":"Ersay","year":"2001","journal-title":"Int Urol Nephrol"},{"key":"10.1002\/jps.24471_bb0245","series-title":"Mathematics for medical and clinical laboratory professionals","first-page":"193","article-title":"Urinalysis and renal clearance","author":"Helms","year":"2008"},{"issue":"4","key":"10.1002\/jps.24471_bb0250","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF00686169","article-title":"Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer","volume":"32","author":"Wientjes","year":"1993","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915300526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915300526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,25]],"date-time":"2019-08-25T07:53:45Z","timestamp":1566719625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354915300526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0022354915300526"],"URL":"https:\/\/doi.org\/10.1002\/jps.24471","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}